A Dimitrios Colevas

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck
    A D Colevas
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Boston MA, USA
    Int J Radiat Oncol Biol Phys 51:599-604. 2001
  2. ncbi request reprint Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
    A Dimitrios Colevas
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 24:2644-52. 2006
  3. ncbi request reprint Development of investigational radiation modifiers
    A Dimitrios Colevas
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 95:646-51. 2003
  4. ncbi request reprint Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
    Marshall R Posner
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 357:1705-15. 2007
  5. pmc Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer
    Deborah Citrin
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 74:1040-6. 2009
  6. ncbi request reprint Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience
    Robert Haddad
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:412-8. 2003
  7. ncbi request reprint Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
    Robert Haddad
    Dana Farber Cancer Institute, Department of Adult Oncology, SW430G, 44 Binney Street, Boston, MA 02115, USA
    Oral Oncol 39:724-7. 2003
  8. ncbi request reprint Organ preservation-induction chemotherapy
    A Dimitrios Colevas
    Investigational Drug Branch, NCI CTEP, Rockville, MD 20852, USA
    Cancer Treat Res 114:213-34. 2003
  9. ncbi request reprint Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent
    A Dimitrios Colevas
    National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD, USA
    Oncology (Williston Park) 18:1778, 1781-2, 1784. 2004
  10. ncbi request reprint Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
    Kathleen W Beekman
    Genitourinary Oncology Service, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
    Clin Genitourin Cancer 4:299-302. 2006

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck
    A D Colevas
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Boston MA, USA
    Int J Radiat Oncol Biol Phys 51:599-604. 2001
    ....
  2. ncbi request reprint Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
    A Dimitrios Colevas
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 24:2644-52. 2006
    ..There is a need for further trials with end points other than overall survival or tumor response in this patient population. Guidelines for patient selection and treatment options are provided...
  3. ncbi request reprint Development of investigational radiation modifiers
    A Dimitrios Colevas
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 95:646-51. 2003
  4. ncbi request reprint Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
    Marshall R Posner
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 357:1705-15. 2007
    ....
  5. pmc Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer
    Deborah Citrin
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Radiat Oncol Biol Phys 74:1040-6. 2009
    ..To report the long-term outcomes and toxicity of a regimen of infusion paclitaxel delivered concurrently with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck...
  6. ncbi request reprint Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience
    Robert Haddad
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:412-8. 2003
    ..In the current analysis, the authors report the data on long-term survival, patterns of failure, and morbidity among the patients who were treated at their institution...
  7. ncbi request reprint Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
    Robert Haddad
    Dana Farber Cancer Institute, Department of Adult Oncology, SW430G, 44 Binney Street, Boston, MA 02115, USA
    Oral Oncol 39:724-7. 2003
    ..Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu. New agents are still needed...
  8. ncbi request reprint Organ preservation-induction chemotherapy
    A Dimitrios Colevas
    Investigational Drug Branch, NCI CTEP, Rockville, MD 20852, USA
    Cancer Treat Res 114:213-34. 2003
  9. ncbi request reprint Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent
    A Dimitrios Colevas
    National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD, USA
    Oncology (Williston Park) 18:1778, 1781-2, 1784. 2004
  10. ncbi request reprint Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
    Kathleen W Beekman
    Genitourinary Oncology Service, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
    Clin Genitourin Cancer 4:299-302. 2006
    ....
  11. ncbi request reprint A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck
    Roy B Tishler
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 95:1472-81. 2002
    ..Patients were treated with weekly docetaxel and concurrent daily fractionated radiation therapy to determine the maximum tolerated dose (MTD) of docetaxel and the efficacy of the regimen...
  12. ncbi request reprint Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
    Philip C Amrein
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 104:1418-27. 2005
    ....
  13. ncbi request reprint Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Patricia A Tang
    Princess Margaret Phase II Consortium, Toronto, ON, Canada
    Invest New Drugs 26:257-64. 2008
    ..In addition, no pharmacodynamic changes were observed in peripheral blood mononuclear cells. We detected no antitumor activity of ispinesib in RMHNSC on this dosing schedule...
  14. ncbi request reprint Patient-reported outcomes and the evolution of adverse event reporting in oncology
    Andy Trotti
    Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
    J Clin Oncol 25:5121-7. 2007
    ..Therefore, care must be used when developing health outcomes and safety data collection plans...
  15. pmc Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
    L Burt Nabors
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
    J Clin Oncol 25:1651-7. 2007
    ..This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma...
  16. ncbi request reprint A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
    Edwin M Posadas
    University of Chicago Phase II Consortium, Section of Hematology Oncology, Chicago, Illinois 60637, USA
    Cancer Biol Ther 6:490-3. 2007
    ..Suggestion of activity in renal cell carcinoma (RCC) has been seen in early clinical studies...
  17. ncbi request reprint A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:335-41. 2007
    ..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure...
  18. pmc Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
    Wells A Messersmith
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Eur J Cancer 43:78-86. 2007
    ..A long half-life and accumulation of BPU and active metabolites were observed, recommending against a continuous administration. Weekly oral BPU therapy should be further tested using an interrupted schedule...
  19. pmc Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:399-404. 2007
    ..Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases...
  20. ncbi request reprint Adverse event reporting in publications compared with sponsor database for cancer clinical trials
    Orit Scharf
    PSI International Inc, Fairfax, VA, USA
    J Clin Oncol 24:3933-8. 2006
    ..We examined whether the published AE data differ from those in the sponsor's database and from the data collection requirements stated in study protocols...
  21. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ....
  22. ncbi request reprint Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  23. ncbi request reprint Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    Susan Burdette-Radoux
    McGill University, Montreal, Quebec, Canada
    Invest New Drugs 22:315-22. 2004
    ..To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system...
  24. ncbi request reprint CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    Andy Trotti
    H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
    Semin Radiat Oncol 13:176-81. 2003
    ..This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0...